Solubility of favipiravir (as an anti-COVID-19) in supercritical carbon dioxide: An experimental analysis and thermodynamic modeling

Improving and measuring the solubility of favipiravir and montelukast in SC-CO2 with ethanol projecting their nanonization

Supercritical carbon dioxide (SC-CO2)-based approaches have become more popular in recent years as alternative methods for creating micro- or nanosized medicines. Particularly, high drug solubility is required in those techniques using SC-CO2 as a solvent. During the most recent pandemic years, favipiravir and montelukast were two of the most often prescribed medications for the treatment of COVID-19. In this study, ethanol at 1 and 3 mol% was utilized as a cosolvent to increase the solubility of both medicines in SC-CO2 by a static approach using a range of temperatures (308 to 338 K) and pressure (12 to 30 MPa) values. The experimentally determined solubilities of favipiravir and montelukast in SC-CO2 + 3 mol% ethanol showed solubility values up to 33.3 and 24.5 times higher than that obtained for these drugs with only SC-CO2. The highest values were achieved in the pressure of 12 MPa and temperature of 338 K. Last but not least, six density-based semi-empirical models with various adjustable parameters were used to perform the modeling of the solubility of favipiravir and montelukast.

Experimental and modeling of solubility of sitagliptin phosphate, in supercritical carbon dioxide: proposing a new association model

The solubility of an anti-hyperglycemic agent drug, (R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro [1,2,4] triazolo[4,3-a] pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl) butan-2-amine (also known as Sitagliptin phosphate) in supercritical carbon dioxide (scCO2) was determined by ananalytical and dynamic technique at different temperatures (308, 318, 328 and 338 K) and pressure (12-30 MPa) values. The measured solubilities were in the range of 3.02 × 10-5 to 5.17 × 10-5, 2.71 × 10-5 to 5.83 × 10-5, 2.39 × 10-5 to 6.51 × 10-5 and 2.07 × 10-5 to 6.98 × 10-5 in mole fraction at (308, 318, 328 and 338) K, respectively. The solubility data were correlated with existing density models and with a new association model.

Solubility measurement of verapamil for the preparation of developed nanomedicines using supercritical fluid

A static method is employed to determine the solubilities of verapamil in supercritical carbon dioxide (SC-CO2) at temperatures between 308 and 338 K and pressures between 12 and 30 MPa. The solubility of verapamil in SC-CO2 expressed as mole fraction are in the range of 3.6 × 10-6 to 7.14 × 10-5. Using four semi-empirical density-based models, the solubility data are correlated: Chrastil, Bartle, Kumar-Johnston (K-J), and Mendez-Santiago and Teja (MST), two equations of state (SRK and PC-SAFT EoS), expanded liquid models (modified Wilson's models), and regular solution model. The obtained results indicated that the regular solution and PC-SAFT models showed the most noteworthy exactness with AARD% of 1.68 and 7.45, respectively. The total heat, vaporization heat, and solvation heat of verapamil are calculated at 39.62, 60.03, and - 20.41 kJ/mol, respectively. Regarding the poor solubility of verapamil in SC-CO2, supercritical anti-solvent methods can be an appropriate choice to produce fine particles of this drug.

Nasal delivery as a strategy for the prevention and treatment of COVID-19

INTRODUCTION

The upper respiratory tract is a major route of infection for COVID-19 and other respiratory diseases. Thus, it appears logical to exploit the nose as administration site to prevent, fight, or minimize infectious spread and treat the disease. Numerous nasal products addressing these aspects have been considered and developed for COVID-19.

AREAS COVERED

This review gives a comprehensive overview of the different approaches involving nasal delivery, i.e., nasal vaccination, barrier products, and antiviral pharmacological treatments that have led to products on the market or under clinical evaluation, highlighting the peculiarities of the nose as application and absorption site and pointing at key aspects of nasal drug delivery.

EXPERT OPINION

From the analysis of nasal delivery strategies to prevent or fight COVID-19, it emerges that, especially for nasal immunization, formulations appear the same as originally designed for parenteral administration, leading to suboptimal results. On the other hand, mechanical barrier and antiviral products, designed to halt or treat the infection at early stage, have been proven effective but were rarely brought to the clinics. If supported by robust and targeted product development strategies, intranasal immunization and drug delivery can represent valid and sometimes superior alternatives to more conventional parenteral and oral medications.

In vitro bio-characterization of solid lipid nanoparticles of favipiravir in A549 human lung epithelial cancer cells

Objectives

Lung cancer is a leading cause of mortality worldwide. In lung cancer treatment, nebulized solid lipid nanoparticles may be a viable drug delivery method, helping the drug reach sites of action, and improving its inhalation efficiency and pulmonary deposition. This research focused on evaluating the effectiveness of solid lipid nanoparticles of favipiravir (Fav-SLNps) in facilitating drug delivery to sites of action in lung cancer treatment.

Methods

The hot-evaporation method was used to formulate Fav-SLNps. The in vitro cell viability, anti-cancer effects, and cellular uptake activity were evaluated in A549 human lung adenocarcinoma cells treated with the Fav-SLNp formulation.

Results

The Fav-SLNps were formulated successfully. Importantly, Fav-SLNps at a concentration of 322.6 μg/ml were found to be safe and non-toxic toward A549 cells in vitro. The formulation had potential anti-proliferative properties via increasing the proportions of cells in G2/M and G0/G1 phases to 1.20 and 1.13 times those in untreated cells. Additionally, Fav-SLNp treatment significantly induced necrosis in A549 cells. Furthermore, the use of SLNps in the Fav formulation resulted in a macrophage drug uptake 1.23 times that of the free drug.

Conclusion

Our results confirmed the internalization and anti-cancer activity of the Fav-SLNp formulation in the A549 lung cancer cell line. Our findings suggest that Fav-SLNps could potentially be used as lung cancer treatment to facilitate drug delivery to sites of action in the lungs.

Supercritical Fluid Extraction from Zataria multiflora Boiss and Impregnation of Bioactive Compounds in PLA for the Development of Materials with Antibacterial Properties

In this research, the extraction with supercritical carbon dioxide (SC-CO2) and the subsequent impregnation of the extracted bioactive compounds from Zataria multiflora Boiss (Z. multiflora) into polylactic acid (PLA) films was investigated. The effects of temperature (318 and 338 K), pressure (15 and 25 MPa) and cosolvent presence (0 and 3 mol%) on the extraction yield were studied. The SC-CO2 assisted impregnation runs were carried out in a discontinuous mode at different pressure (15 and 25 MPa), temperature (318 and 328 K), and time (2 and 8 h) values, using 0.5 MPa min−1 as a constant value of depressurization rate. ANOVA results confirmed that pressure, temperature, and time influenced the extraction yield. Moreover, antioxidant activities of extracts of Z. multiflora were evaluated using 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging assays. In addition, the antibacterial activities of the extracts were screened against standard strains of Staphylococcus aureus (S. aureus) and Escherichia coli (E. coli). The results of this investigation indicated that extracts obtained from the aerial parts of Z. multiflora possessed antioxidant and antibacterial properties. The impregnated samples presented strong antibacterial activity against the selected microorganisms.